Magnetic Resonance Mammography in the Diagnostics of Intraduсtal Cancer in situ (DCIS)
https://doi.org/10.52560/2713-0118-2021-3-41-61
Abstract
The improvement of methods of radiation diagnostics has led to an increase in the frequency of detection of breast cancer in the early stages. According to our study (a retrospective analysis of data from 195 MRM with DKU), the results of studies of women with a histologically verified diagnosis of intra-ductal carcinoma in situ (DCIS). For formations of more than 5 mm in 60 %, we obtained reliable criteria for the malignant process (contrast capture of more than 100 % for type II-III, the presence of feeding arteries). Various contrast zones without / or with the presence of less than 5 mm formation in 10–20 % of in situ carcinomas had a pattern of accumulation similar to benign proliferative changes, a statistically significant criterion was the strengthening of the vasculature on MIP reconstruction around the contrast zone, which in 31 % of cases coincided with the areas of accumulation of atypical microcalcinates detected in mammography (BI-RADS 4). MR mammography with dynamic contrast enhancement, having a high sensitivity in detecting vascularized areas, allows us to assess their nature with a high degree of probability against the background of any types of breast tissue structure.
About the Authors
S. V. Serebryakova
Federal State Budgetary Institute «The Nikiforov Russian Center of Emergency and Radiation Medicine» The Ministry of Russian Federation for Civil Defense, Emergencies and Elimination of Consequences of Natural Disasters; Federal State Budgetary Educational Institution of Higher Education «Academician I. P. Pavlov First St. Petersburg State Medical University” of the Ministry of Healthcare of Russian Federation
Russian Federation
Russian Federation
Serebryakova Svetlana Vladimirovna, M. D. Med., Professor of the Department of Therapy and Integrative Medicine of the Institute of Continuing Professional Education «Extreme Medicine», Head of the MRI office of Clinic № 1
4/2, ul. Academica Lebedeva, St. Petersburg, 194044
+7 (812) 339-39-39
T. A. Shumakova
Federal State Budgetary Educational Institution of Higher Education «Academician I. P. Pavlov First St. Petersburg State Medical University” of the Ministry of Healthcare of Russian Federation
Russian Federation
Russian Federation
Shumakova Tatyana Anatolyevna, Ph. D. Med., Associate Professor of the Department of Radiology and Radiation Medicine, Head of MRI Department, Saint-Petersburg I. I. Dzhanelidze Research Institute of Emergency Medicine
3, ul. Budapeshtskaya, Saint-Petersburg, 192242
+7 (921) 994-54-40
O. B. Safronova
Federal State Budgetary Educational Institution of Higher Education «North-Western State Medical University named after I. I. Mechnikov», Ministry of Healthcare of Russian Federation
Russian Federation
Russian Federation
Safronova Olga Borisovna, Ph. D. Med., Associate Professor of Department of Radiology and Radiation
3/5, 2 al. Berezovaya, 197022, St-Petersburg
+7 (812) 607-06-75
E. A. Yuhno
S. M. Kirov Military Medical Academy, Ministry of Defense of Russia
Russian Federation
Russian Federation
Yukhno Elena Antonovna, Ph. D. Med., Radiologist, Chief of the Department of Diagnostic Radiology of Clinic of Roentgenoradiology and Ultrasound Diagnostics
6, ul. Academica Lebedeva, St. Petersburg, 194044
+7 (812) 292-33-47
A. L. Serebryakov
Federal State Budgetary Institution «Almazov National Medical Research Centre» of the Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
Serebryakov Artem Leonidovich, Resident of the Department of Radiology and Medical Visualization
2, ul. Akkuratova, St. Petersburg, 197341
+7(931)340-37-47
References
1. Kaprin A. D., Starinskiy V. V., Shahzodovoy A. O. Malignancies in Russia in 2019 (morbidity and mortality). Moscow, 2020. 252 (in Russian).
2. Korzhenkova G. P. The first results of a pilot mammoscreening project for the early detection of breast cancer in the Kaluga region. Consilium Medicum. 2019. V. 21 (6). P. 38–41 (in Russian.).
3. Portnoy S. M. Main risk factors for breast cancer and proposals for its prevention. Tumors of female reproductive system. 2018. V. 14 (3). P. 25–39. (in Russian).
4. Semiglazov V. V. Clinical characteristics and treatment of non-invasive and minimally invasive forms of breast cancer. St. Petersburg: Aesculapius, 2004. 47 p. (in Russian.).
5. Serebrjakova S. V., Trufanov G. E., Fokin V. A., Juhno E. A. The magnetic resonance mammography with dynamic contrast enhancement in the differential diagnostics of breast nodes. Visualization in medicine 2016. No. 1. Р. 10–21 (in Russian).
6. Shumakova T. A., Solntseva I. A., Safronova O. B., Savello V. E., Serebryakova S. V. Application of the international BI-RADS classification in mammology: a guide for physicians. St Petersburg: ELBI-SPb, 2018 (in Russian).
7. Cardoso F., Kyriakides S., Ohno S. ESMO Clinical Practice Guidelines. Early Breast Cancer. 2019. No. 30. P. 1194 – 1220.
8. Gradishar W. J., Anderson B. O., Balassanian R. et al. Invasive breast cancer version 1.2016, NCCN Clinical Practice Guidelines in Oncology. J. Natl. Compr. Canc. Netw. 2016. No. 14 (3). P. 324–354.
9. Hartmann L. C., Degnim A. C., Santen R. J. et al. Atypical hyperplasia of the breast-risk assessment and management options. N. Engl. J. Med. 2015. Jan 1. No. 372 (1). P. 78–89.
10. Holland R., Faverly D. R. Whole-organ studies // Silverstein M. J., ed. Ductal carcinoma in situ of the breast. Baltimore: Williams and Wilkins, 1997. P. 233–240.
11. Morrow M., Schnitt S. J., Norton L. Current management of lesions associated with an increased risk of breast cancer. Nat. Rev. Clin. Oncol. 2015. Apr. No. 12 (4). P. 227–238.
12. Petrelli F., Viale G., Cabiddu M., Barni S. Prognostic value of different cut-off levels of Ki-67 in breast cancer: a systematic review and meta-analysis of 64 196 patients. Breast Cancer Res. Treat. 2015. No. 153 (3). P. 477–491.
13. Silverstein M. J., Lagios M. D. Use of predictors of recurrence to plan therapy for DCIS of the breast. Oncol. (Williston Park). 1997. Mar. No. 11 (3). P. 393–406, 409–10.
14. Turnbull A. K., Arthur L. M., Renshaw L. et al. Accurate prediction and validation of response to endocrine therapy in breast cancer. J. Clin. Oncol. 2015. No. 33 (20). P. 2270–2278.
15. Wang M., He X., Chang Y., Sun G., Thabane L. A sensitivity and specificity comparison of fine needle aspiration cytology and core needle biopsy in evaluation of suspicious breast lesions: A systematic review and meta-analysis. Breast. 2017. No. 31. P. 157–166.
16. Wolff A. C., Hammond M. E. H., Allison K. H. et al. HER2 testing in breast cancer: american society of clinical oncology// college of american pathologists clinical practice guideline focused update summary. J. Oncol. Pract. 2018. No. 14 (7). P. 437–441.
17. Wolff A. C., Hammond M. E. H., Allison K. H. et al. Human epidermal growth factor receptor testing in breast cancer: american society of clinical oncology. College of American pathologists clinical practice guideline focused update. J. Clin. Oncol. 2018. No. 36 (20). P. 2105–2122.
18. Zhang X. H., Xiao C. Diagnostic value of nineteen different imaging methods for patients with breast cancer: a network meta-analysis. Cell Physiol Biochem. 2018. No. 46 (5). P. 2041–2055.
Review
For citations:
Serebryakova S.V., Shumakova T.A., Safronova O.B., Yuhno E.A., Serebryakov A.L. Magnetic Resonance Mammography in the Diagnostics of Intraduсtal Cancer in situ (DCIS). Radiology - Practice. 2021;(3):41-61. (In Russ.) https://doi.org/10.52560/2713-0118-2021-3-41-61
Views:
1044
Email this article 